Tricia Branker

Experience: Securities Offerings and Transactions: Represented Ono Pharmaceutical Co., Ltd., a Japan-based global specialty pharmaceutical company, in its tender offer for $2.4 billion of securities of Deciphera Pharmaceuticals, Inc.; Represented Bowman Consulting Group Ltd. in its shelf offering of approximately $50 million of common stock and in its follow-on public offering of common stock; Represented Kismet One Acquisition Corp., Kismet Two Acquisition Corp. and Kismet Three Acquisition Corp. in connection with their initial public offerings of an aggregate of $767.5 million and listing on Nasdaq; Represented Golden Falcon Acquisition Corp. in connection with its $345 million initial public offering and listing on NYSE; Represented Golden Arrow Merger Corp. in connection with its $250 million initial public offering and listing on Nasdaq; Represented Quantum FinTech Acquisition Corporation in connection with its $175 million initial public offering and listing on NYSE; Represented Cowen and Company, LLC as underwriters in connection with MCAP Acquisition Corporation's $316.2 million initial public offering and listing on Nasdaq; Represented Advanced Merger Partners, Inc. in connection with its $287.5 million initial public offering and listing on NYSE; Represented AtlasClear Holdings, Inc. in its business combination with Quantum FinTech Acquisition Corporation, a publicly traded SPAC; Represented Golden Arrow Merger Corp., a publicly traded SPAC, in its pending business combination with Bolt Threads, Inc.; Public Company Representation: Represented various public companies in connection with Exchange Act reporting, preparation of shelf registration statements and corporate governance-related matters.